Skip to content
Screener

Avalo Therapeutics AVTX Q4 2025 Annual earnings

Reported March 23, 2026 · Before market open

Revenue$59.0KIn line
EPS-$0.37Beat by $1.17
Revenue estimate$59.0K
EPS estimate-$1.54

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.56

Financials

Q4 2025

Income statement

See full
Revenue$59.0K-69.3%
Operating income-$19.7M-48.3%
Net income-$13.7M+61.2%
EPS (diluted)-$0.37—

Balance sheet

See full
Cash & equivalents$16.1M-88.0%
Total debt$427.0K-53.5%
Total equity$83.0M-37.6%
Total assets$116.5M-22.7%

Cash flow

See full
Operating cash flow-$14.2M+5.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$329.31M+324%
Enterprise value$313.63M+660%

Returns & leverage

See full
Return on equity-72.4%+58.5pp
Debt / equity0×0.0×
Current ratio8.1×-11.8×

FAQ

When did Avalo Therapeutics report Q4 2025 earnings?
Avalo Therapeutics (AVTX) reported Q4 2025 earnings on March 23, 2026 before market open.
What were Avalo Therapeutics's Q4 2025 revenue and EPS?
Avalo Therapeutics reported revenue of $59.0K and eps of $-0.37 for Q4 2025.
Did Avalo Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $59.0K by -. EPS beat the consensus estimate of $-1.54 by $1.17.
How did Avalo Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 69.3% from $192.0K a year earlier and eps grew 95.3% from $-7.95.
Where can I find Avalo Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001534120-26-000010) and the 10-K periodic report (0001534120-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.